nach oben

Erschienen in:

01.12.2018 | Original Paper

Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer

verfasst von: Rohit Mehra, Simpa S. Salami, Robert Lonigro, Ritu Bhalla, Javed Siddiqui, Xuhong Cao, Daniel E. Spratt, Ganesh S. Palapattu, Nallasivam Palanisamy, John T. Wei, Arul M. Chinnaiyan, Scott A. Tomlins

Erschienen in: Medical Oncology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

We have previously demonstrated a significant correlative relationship between PTEN deletion and ERG rearrangement, both in the development of clinically localized prostate cancers and metastases. Herein, we evaluate the cooperative role of ERG and PTEN in oncological outcomes after radical prostatectomy for clinically localized prostate cancer. We evaluated ERG and PTEN status using three previously described cohorts. The first cohort included 235 clinically localized prostate cancer cases represented on tissue microarrays (TMA), evaluated using previously validated FISH assays for ERG and PTEN. The second cohort included 167 cases of clinically localized prostate cancer on TMAs evaluated for PTEN by FISH, and for PTEN and ERG by dual IHC. The third cohort comprised 59 clinically localized prostate cancer cases assessed by array comparative genomic hybridization (aCGH). Kaplan–Meir plots and long rank tests were used to assess the association of ERG and PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. Of the 317 cases eligible for analyses with evaluable ERG and PTEN status, 88 (27.8%) patients developed biochemical recurrence over a median follow-up of 5.7 years. Overall, 45% (142/317) of cases demonstrated ERG rearrangement and 20% (62/317) of cases demonstrated PTEN loss. Hemizygous and homozygous deletion of PTEN was seen in 10% (18/175) and 3% (5/175) of ERG-negative cases, respectively. In contrast, hemizygous and homozygous deletion of PTEN was seen in 11% (15/142) and 17% (24/123) of ERG-positive cases, respectively. PTEN loss (heterozygous or homozygous) was significantly associated with shorter time to biochemical recurrence compared to no PTEN loss (p < 0.001). However, ERG rearrangement versus no rearrangement was not associated with time to PSA recurrence (p = 0.15). Patients who exhibited ERG rearrangement and loss of PTEN had no significant difference in time to recurrence compared to patients with wild-type ERG and loss of PTEN (p = 0.30). Our findings confirm a mutual cooperative role of ERG and PTEN in the pathogenesis of prostate cancer, particularly for homozygous PTEN deletion. ERG did not stratify outcome either alone or in combination with PTEN in this cohort.

Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011;3:111ra121–1. https://doi.org/10.1126/scitranslmed.3003161.CrossRefPubMedPubMedCentral

Jiang B-H, Liu L-Z. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta. 2008;1784:150–8. https://doi.org/10.1016/j.bbapap.2007.09.008.CrossRefPubMed

Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009;4:127–50. https://doi.org/10.1146/annurev.pathol.4.110807.092311.CrossRefPubMedPubMedCentral

Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets. 2009;9:237–49.CrossRef

Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–8. https://doi.org/10.1126/science.1117679.CrossRefPubMed

Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006;66:3396–400. https://doi.org/10.1158/0008-5472.CAN-06-0168.CrossRefPubMed

Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007;448:595–9. https://doi.org/10.1038/nature06024.CrossRefPubMed

Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 2008;68:73–80. https://doi.org/10.1158/0008-5472.CAN-07-5352.CrossRefPubMed

Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol. 2007;20:538–44. https://doi.org/10.1038/modpathol.3800769.CrossRefPubMed

10.

Mehra R, Tomlins SA, Yu J, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 2008;68:3584–90. https://doi.org/10.1158/0008-5472.CAN-07-6154.CrossRefPubMedPubMedCentral

11.

Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008;10:177–88.CrossRef

12.

Klezovitch O, Risk M, Coleman I, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA. 2008;105:2105–10. https://doi.org/10.1073/pnas.0711711105.CrossRefPubMed

13.

Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009;41:619–24. https://doi.org/10.1038/ng.370.CrossRefPubMedPubMedCentral

14.

Zong Y, Xin L, Goldstein AS, et al. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci USA. 2009;106:12465–70. https://doi.org/10.1073/pnas.0905931106.CrossRefPubMed

15.

King JC, Xu J, Wongvipat J, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009;41:524–6. https://doi.org/10.1038/ng.371.CrossRefPubMedPubMedCentral

16.

Krohn A, Diedler T, Burkhardt L, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol. 2012;181:401–12. https://doi.org/10.1016/j.ajpath.2012.04.026.CrossRefPubMed

17.

Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009;22:1083–93. https://doi.org/10.1038/modpathol.2009.69.CrossRefPubMedPubMedCentral

18.

Yoshimoto M, Ding K, Sweet JM, et al. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol. 2013;26:435–47. https://doi.org/10.1038/modpathol.2012.162.CrossRefPubMed

19.

Bismar TA, Yoshimoto M, Vollmer RT, et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int. 2011;107:477–85. https://doi.org/10.1111/j.1464-410X.2010.09470.x.CrossRefPubMed

20.

Bhalla R, Kunju LP, Tomlins SA, et al. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. Mod Pathol. 2013;26:835–48. https://doi.org/10.1038/modpathol.2012.234.CrossRefPubMedPubMedCentral

21.

Korshunov A, Sycheva R, Gorelyshev S, et al. Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. Mod Pathol. 2005;18:1258–63. https://doi.org/10.1038/modpathol.3800415.CrossRefPubMed

22.

Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer. 2007;97:678–85. https://doi.org/10.1038/sj.bjc.6603924.CrossRefPubMedPubMedCentral

23.

Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol. 2008;21:1451–60. https://doi.org/10.1038/modpathol.2008.96.CrossRefPubMed

24.

Grasso CS, Wu Y-M, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239–43. https://doi.org/10.1038/nature11125.CrossRefPubMedPubMedCentral

25.

Grasso CS, Cani AK, Hovelson DH, et al. Integrative molecular profiling of routine clinical prostate cancer specimens. Ann Oncol. 2015;26:1110–8. https://doi.org/10.1093/annonc/mdv134.CrossRefPubMedPubMedCentral

26.

Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000;100:387–90.CrossRef

27.

Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8:497–511. https://doi.org/10.1038/nrc2402.CrossRefPubMedPubMedCentral

28.

Bismar TA, Yoshimoto M, Duan Q, et al. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer. Histopathology. 2012;60:645–52. https://doi.org/10.1111/j.1365-2559.2011.04116.x.CrossRefPubMed

29.

Liu S, Yoshimoto M, Trpkov K, et al. Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone. Cancer Biol Ther. 2011;11:562–6.CrossRef

30.

Lahdensuo K, Erickson A, Saarinen I, et al. Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. Mod Pathol. 2016;29:1565–74. https://doi.org/10.1038/modpathol.2016.154.CrossRefPubMed

31.

Chaux A, Peskoe SB, Gonzalez-Roibon N, et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol. 2012;25:1543–9. https://doi.org/10.1038/modpathol.2012.104.CrossRefPubMedPubMedCentral

32.

Lotan TL, Gumuskaya B, Rahimi H, et al. Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Mod Pathol. 2013;26:587–603. https://doi.org/10.1038/modpathol.2012.201.CrossRefPubMed

33.

Trotman LC, Niki M, Dotan ZA, et al. PTEN dose dictates cancer progression in the prostate. PLoS Biol. 2003;1:E59. https://doi.org/10.1371/journal.pbio.0000059.CrossRefPubMedPubMedCentral

34.

Udager AM, Alva A, Mehra R. Current and proposed molecular diagnostics in a genitourinary service line laboratory at a tertiary clinical institution. Cancer J. 2014;20:29–42. https://doi.org/10.1097/PPO.0000000000000017.CrossRefPubMed

35.

Brenner JC, Ateeq B, Li Y, et al. Mechanistic rationale for inhibition of poly(ADP-Ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011;19:664–78. https://doi.org/10.1016/j.ccr.2011.04.010.CrossRefPubMedPubMedCentral

36.

Feng FY, Brenner JC, Hussain M, et al. Molecular pathways: targeting ETS gene fusions in cancer. Clin Cancer Res. 2014;20:4442–8. https://doi.org/10.1158/1078-0432.CCR-13-0275.CrossRefPubMedPubMedCentral

37.

Hussain M, Daignault-Newton S, Twardowski PW, et al. Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012. J Clin Oncol. 2018;36(10):991–9.CrossRef

38.

Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–7.CrossRef

39.

Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004;22:2954–63. https://doi.org/10.1200/JCO.2004.02.141.CrossRefPubMed

40.

Arkenau H-T, Mateo J, Lemech CR, et al. A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors. ASCO Meeting Abstracts. 2014;32:2514.

41.

Blackman SC, Gainer SD, Suttle BB, et al. Abstract 1752: a phase I/IIa, first time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency. Cancer Res. 2012;72:1752–2. https://doi.org/10.1158/1538-7445.AM2012-1752.CrossRef

42.

Jamaspishvili T, Berman DM, Ross AE, et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018;15(4):222–34.CrossRef

Titel: Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer
verfasst von: Rohit Mehra
Simpa S. Salami
Robert Lonigro
Ritu Bhalla
Javed Siddiqui
Xuhong Cao
Daniel E. Spratt
Ganesh S. Palapattu
Nallasivam Palanisamy
John T. Wei
Arul M. Chinnaiyan
Scott A. Tomlins
Publikationsdatum: 01.12.2018
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 12/2018
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-018-1212-6

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2018

Contemporary treatment of metastatic renal cell carcinoma

Letter to the editor regarding “Ultrasound features of breast cancer for predicting axillary lymph node metastasis”

Testicular teratomas: a growing problem?

Second-generation inflammation-related scores are more effective than systemic inflammation ratios in predicting prognosis of patients with unresectable or metastatic pancreatic cancer receiving cytotoxic chemotherapy

Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues

Autotaxin is a novel molecular identifier of type I endometrial cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie